Open AccessThe multiarm optimization of stroke thrombolysis phase 3 acute stroke randomized clinical trial: Rationale and methods
Author(s) -
S Iris Deeds,
Andrew D Barreto,
Jordan Elm,
Colin P. Derdeyn,
Scott M. Berry,
Pooja Khatri,
Claudia S. Moy,
Scott Janis,
Joseph P. Broderick,
James C. Grotta,
Opeolu Adeoye
Publication year - 2020
Publication title -
international journal of stroke
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.375
H-Index - 74
eISSN - 1747-4949
pISSN - 1747-4930
DOI - 10.1177/1747493020978345
Subject(s) - medicine , eptifibatide , thrombolysis , argatroban , stroke (engine) , placebo , tissue plasminogen activator , bolus (digestion) , clinical trial , randomized controlled trial , anesthesia , surgery , myocardial infarction , platelet , thrombin , mechanical engineering , alternative medicine , pathology , conventional pci , engineering
Intravenous recombinant tissue plasminogen activator is the only proven effective medication for the treatment of acute ischemic stroke. Two approaches that may augment recombinant tissue plasminogen activator thrombolysis and prevent arterial reocclusion are direct thrombin inhibition with argatroban and inhibition of the glycoprotein 2b/3a receptor with eptifibatide.